Merck & Company | StockChase
162
Merck & Company (MRK-N)

Last Price Recorded: $55.2000 on 2017-11-17

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Merck & Company


Signal Opinion Expert

2017-11-07

COMMENT
Merck & Company (MRK-N)

Unfortunately, pharmas/biotech have had a bit of a rough go. It was the mega-caps, not the small guys. This one reason he likes using ETF's in his mix. He prefers using the Spider S&P Biotech ETF (XBI-N).

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Management

Price: $55.590
Owned: No

2017-09-14

TOP PICK
Merck & Company (MRK-N)

He likes their leadership in drug therapies.  They have their HEP-C and diabetes franchises.  It is an easy hold for him.  They are well diversified.  They are number 3 in animal health products.  It has a PE of 15.5 times next year’s earnings.  (Analysts’ target: $70.00).

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $66.120
Owned: Yes

2017-09-14

PAST TOP PICK
Merck & Company (MRK-N)

(Top Pick Feb 22/17, Up 3%)  It has traded in line with others.  It is a wonderfully run company with a deep pipeline into diabetes and arthritis.  They are in the forefront of immunotherapies for arthritis.  They are the leaders.  15.5 times forward earnings.  It should trade in a double digit PE.  He likes it for leadership and diversification. 

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $66.120
Owned: Yes

2017-06-21

DON'T BUY
Merck & Company (MRK-N)

Pfizer (PFE-N) or Merck (MRK-N)? Neither. These companies did very, very well back in the last part of the last century. Patent protection laws really haven’t given them enough of a boost to be able to cover the enormous costs of developing and testing the drugs, and there is a high failure rate. The companies have made massive consolidations. They’ve tried to grow by spending less. He would look at the Bio-Pharma area instead, such as Biogen (BIIB-Q) or Celgene (CELG-Q). Financially, these companies are in good shape and are growing.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $65.460
Owned: Unknown

2017-05-10

PAST TOP PICK
Merck & Company (MRK-N)

(A Top Pick Feb 22/17. Up 30.86%.) His thesis on this was that this was one of the leaders in immuno ecology.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $63.940
Owned: Yes

2017-02-22

PAST TOP PICK
Merck & Company (MRK-N)

(A Top Pick June 22/16. Up 16.19%.) The one thing he liked about this was the diversified pipeline, but really it was their immuno oncology drug that has been the front runner.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $65.290
Owned: Yes

2017-02-22

TOP PICK
Merck & Company (MRK-N)

This company has the Mojo right now. Their drugs are definitely working. They have the first-line treatment in very specific lung cancer. Has a huge pipeline of trials going on with Keytruda. He continues to think immuno oncology is fast growing and that there is going to be further positive results coming out over the next couple of years. Dividend yield of 2.88%. (Analysts’ price target is $69.11.)

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $65.290
Owned: Yes

2017-01-27

COMMENT
Merck & Company (MRK-N)

Merck (MRK-N) or Johnson & Johnson (JNJ-N) for safety? For safety, he would attribute that more to J&J. This one is a little more growth oriented. They are spending a lot on research and development and looking at growing their current product offerings. That’s great for a longer-term investor.

biotechnology/pharmaceutical
Kash Pashootan

Sr. VP & Portfolio Manager, First Avenue Advisory, Raymond James

Price: $61.750
Owned: Unknown

2017-01-25

COMMENT
Merck & Company (MRK-N)

They’ve had great success in their drug for lung cancer. Lung cancer is about a 5th of the demand for immuno ecology agents, but the balance of the market is 4X larger and consists of many indications. If you look at who is in the lead, it is more often Bristol-Myers (BMY-N) than this company. Merck had incorrectly been left behind on valuation, but that has now been lifted. Capital markets are looking at who wins and who loses in immunology as an absolute, but that is not the case, it is going to be a balance between the 2. This is a fine company and the valuation is reasonable, but he would rather be with Bristol-Myers. (See Top Picks.)

biotechnology/pharmaceutical
Dr. Richard Evans

Head of Healthcare Practice, SSR

Price: $61.080
Owned: Unknown

2016-10-28

PAST TOP PICK
Merck & Company (MRK-N)

(Top Pick Nov 23/15, Up 14.41%) It has fulfilled what he thought.  It has a multiyear pipeline of drugs still coming.

biotechnology/pharmaceutical
Bruce Campbell (1)

President, Campbell and Lee InvMngmnt

Price: $59.300
Owned: Yes

2016-08-03

COMMENT
Merck & Company (MRK-N)

The difficulty that chemically based pharmaceuticals have had is basically with current legislation. They spend a lot of money developing drugs, and then they go off patent in a few years and they lose that revenue stream. If you look at the financials of all of the majors, basically it is a flat revenue picture, and any cash flow or earnings progress is made through cost cutting. He would prefer the bio side, such as Biogen (BIIB-Q), Celgene (CELG-Q), etc.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $57.650
Owned: Unknown

2016-06-22

TOP PICK
Merck & Company (MRK-N)

He likes the balance sheet and the income he is getting from this. They have a hepatitis C drug that is coming out as well as a great oncology drug. They have 26 phase 3 trials. Sees a slight increase in revenues over the next 2 years. Dividend yield of 3.22%.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $57.040
Owned: Yes

2016-03-15

PAST TOP PICK
Merck & Company (MRK-N)

(A Top Pick March 16/15. Down 5.13%.) Has an 8-9% organic growth over the next 5-year model. A lot of new drugs are coming on. Every time it dips to $50, he adds for new clients. Dividend yield of 3.5%. Looking for high $50-$60 in the next year.

biotechnology/pharmaceutical
Bruce Campbell (1)

President, Campbell and Lee InvMngmnt

Price: $52.420
Owned: Yes

2016-01-28

HOLD
Merck & Company (MRK-N)

One of the blue chip pharma companies out there that will do well if you buy it and tuck it away for a while in an uncertain world while it pays you a good divided. With people getting older and a bigger need for drugs, they have a lot of patents and a good pipeline.

biotechnology/pharmaceutical
Colin Stewart

CEO & Portfolio manager, JC Clark Investments Ltd.

Price: $49.200
Owned: Unknown

2015-12-15

HOLD
Merck & Company (MRK-N)

Don’t sell because you’ve done well.  They have a pretty good pipeline.  If they continue to do good things, don’t pull the trigger, just watch it.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $52.900
Owned: Unknown

Showing 1 to 15 of 162 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.